Q-omics provides the consensus-scored ARMCX7P profile across patient tissues and cancer cell-line models. ARMCX7P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ARMCX7P is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, ARMCX7P RNA expression shows 4,725 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight KIRP, THCA, and OV as cancer lineages where ARMCX7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMCX7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMCX7P survival associations across molecular data types. ARMCX7P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMCX7P RNA expression–survival associations across cancer types. High ARMCX7P expression shows unfavorable associations in KIRP, READ, KIRC, LIHC and COAD, but favorable associations in KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ARMCX7P RNA expression.
This table summarizes ARMCX7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARMCX7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMCX7P shows lower tumor expression in BLCA, PRAD and PAAD and higher tumor expression in THCA and HNSC. The THCA box plot shows higher ARMCX7P RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with ARMCX7P in patient tissues and cancer cell lines. In patient samples, ARMCX7P shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
